Efficacy of bacteriophage treatment in murine burn wound infection induced by Klebsiella pneumoniae

Journal of Microbiology and Biotechnology

Volumn 19, Issue 6, 2009, Pages 622-628

  Kumari, Seema ^a   Harjai, Kusum ^a   Chhibber, Sanjay ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Bacteriophages; Burn wound infection; Histopathological examination; Klebsiella pneumoniae; Phage therapy; Sewage samples

Indexed keywords

KLEBSIELLA PHAGE KPN12; KLEBSIELLA PHAGE KPN13; KLEBSIELLA PHAGE KPN17; KLEBSIELLA PHAGE KPN22; KLEBSIELLA PHAGE KPN5; NATURAL PRODUCT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; BACTERIOPHAGE; BURN INFECTION; CELL REGENERATION; CONTROLLED STUDY; HISTOPATHOLOGY; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; LETHARGY; MORBIDITY; MORTALITY; NONHUMAN; RAT; SINGLE DRUG DOSE; SKIN CELL; SURVIVAL RATE;

ANIMALS; BACTERIOPHAGES; BIOLOGICAL THERAPY; BURNS; COLONY COUNT, MICROBIAL; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICE; MICE, INBRED BALB C; SKIN; TIME FACTORS; TREATMENT OUTCOME; WOUND INFECTION;

ANIMALIA; BACTERIA (MICROORGANISMS); KLEBSIELLA; KLEBSIELLA PNEUMONIAE; MURINAE; MUS;

EID: 68049111226     PISSN: 10177825     EISSN: 17388872     Source Type: Journal    
DOI: 10.4014/jmb.0808.493     Document Type: Article

References (35)

1. Adams, M. (ed.). 1959. Bacteriophages. Interscience Publishers, London, United Kingdom.
2. Benedict, L. R. N. and R. S. Flamiano. 2004. Use of bacteriophages as therapy for Escherichia coli-induced bacteremia in mouse models. Phil. J. Microbiol. Infect. Dis. 33: 47-51.
3. Biswas, B., S. Adhya, P. Washart, B. Paul, A. N. Trostel, B. Powell, R. Carlton, and C. R. Merril. 2002. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect. Immun. 70: 204-210.
4. Brans, T. A., R. P. Dutrieux, M. J. Hoekstra, R. W. Kreis, and J. S. du Pont 1994. Histopathological evaluation of scalds and contact burns in the pig model. Burns 20: 548-551.
5. Bruttin, A. and H. Brussow. 2005. Human volunteers receiving Escherichia coli phage T4 orally: A safety test of phage therapy. Antimicrob. Agents Chemother. 49: 2874-2878.
6. Capparelli, R., I. Ventimiglia, S. Roperto, D. Fenizia, and D. Iannelli. 2006. Selection of an Escherichia coli O157:H7 bacteriophage for persistence in the circulatory system of mice infected experimentally. Clin. Microbiol. Infect. 12: 248-253.
7. Casewell, M. W. and I. Phillips. 1981. Aspects of the plasmid mediated antibiotic resistance and epidemiology of Klebsiella species. Am. J. Med. 70: 459-462.
8. Cerveny, K. E., A. DePaola, D. H. Duckworth, and P. A. Gulig. 2002. Phage therapy of local and systemic disease caused by Vibrio vulnificus in iron-dextran-treated mice. Infect. Immun. 70: 6251-6262.
9. Church, D., S. Elsayed, O. Reid, B. Winston, and R. Lindsay. 2006. Burn wound infections. Clin. Microbiol. Rev. 19: 403-434.
10. Cryz, S. J. Jr., E. Furer, and R. Germanier. 1984. Experimental Klebsiella pneumoniae burn wound sepsis: Role of capsular polysaccharide. Infect. Immun. 43: 440-441.
11. Dale, R. M., K. G. Schnell, and J. P. Wong. 2004. Therapeutic efficacy of "Nubiotics" against burn wound infection by Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 48: 2918-2923.
12. Danelishvili, L., L. S. Young, and L. E. Bermudez. 2006. In vivo efficacy of phage therapy for Mycobacterium avium infection as delivered by a nonvirulent Mycobacterium. Microb. Drug Resist. 12: 1-6.
13. Inal, J. M. 2003. Phage therapy: A reappraisal of bacteriophages as antibiotics. Arch. Immunol. Ther. Exp. (Warsaw) 51: 237-244.
14. Ioseliani, G. D., G. D. Meladze, N. S. Chkhetiia, M. G. Mebuke, and N. I. Kiknadze. 1980. Use of bacteriophage and antibiotics for prevention of acute postoperative empyema in chronic suppurative lung diseases. Grudn. Khir. 6: 63-67.
15. Kehinde, A. O., S. A. Ademola, A. O. Okesola, O. M. Oluwatosin, and R. Bakare. 2004. Pattern of bacterial pathogens in burn wound infections in Ibadan, Nigeria. Ann. Burns Fire Disast. 17: 12-15.
16. Levin, B. and J. J. Bull. 1996. Phage therapy revisited: The population biology of a bacterial infection and its treatment with bacteriophage and antibiotics. Am. Nat. 147: 881-898.
17. Loc Carrillo, C. L., R. D. J. Atterbury, A. El-Shibiny, P. L. Connerton, E. Dillon, A. Scott, and I. F. Connerton. 2005. Bacteriophage therapy to reduce Campylobacter jejuni colonization of broiler chickens. Appl. Environ. Microbiol. 71: 6554-6563.
18. Lorch, A. 1999. Bacteriophages: An alternative to antibiotics? Biotech. Develop. Monitor 39: 14-17.
19. Matsuzaki, S., M. Yasuda, H. Nishikawa, M. Kuroda, T. Ujihara, T. Shuin, et al. 2003. Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage Φ MR11. J. Infect. Dis. 187: 613-624.
20. Matsuzaki, S., M. Rashel, J. Uchiyma, T. Ujihara, M. Kuroda, M. Ikeuchi, M. Fujieda, J. Wakiguchi, and S. Imai. 2005. Bacteriophage therapy: A revitalized therapy against bacterial infectious diseases. J. Infect. Chemother. 11: 211-219.
21. McVay, C., S. M. Velasquez, and J. A. Fralick. 2007. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob. Agents Chemother. 51: 1934-1938.
22. Merril, C. R., B. Biswas, R. Carlon, N. C. Jensen, G. J. Creed, S. Zullo, and S. Adhya. 1996. Long-circulating bacteriophage as antibacterial agents. Proc. Natl. Acad. Sci. U.S.A. 93: 3188-3192.
23. Nasser, S., A. Mabrouk, and A. Maher. 2003. Colonization of burn wounds in Ain Shams University Burn Unit. Burns 29: 229-233.
24. Ozumba, U. C. and B. C. Jiburum. 2000. Bacteriology of burn wounds in Enugu, Nigeria. Burns 26: 178-180.
25. Paissano, A. F., B. Spira, S. Cai, and A. C. Bombana. 2004. In vitro antimicrobial effects of bacteriophages on human dentin infected with Enterococcus faecalis ATCC 29212. Oral Microbiol. Immunol. 19: 327-330.
26. Rumbaugh, K. P., J. A. Griswold, B. H. Iglewski, and A. N. Hamood. 1999. Contribution of quorum sensing to the virulence of Pseudomonas aeruginosa in burn wound infections. Infect. Immun. 67: 5854-5862.
27. Schembri, M. A., J. Blom, A. K. Krogfelt, and P. Klemm. 2005. Capsule and fimbria interaction in Klebsiella pneumoniae. Infect. Immun. 73: 4626-4633.
28. Signori, M., S. Grappolini, E. Magliano, and L. Donati. 1992. Updated evaluation of the activity of antibiotics in a burn center. Burns 18: 500-503.
29. Smith, H. W. and M. B. Huggins. 1982. Successful treatment of experimental Escherichia coli infections in mice using phages: Its general superiority over antibiotics. J. Gen. Microbiol. 128: 307-318.
30. Stroj, L., B. Weber-Dabrowska, K. Partyka, M. Mulczyk, and M. Wojcik. 1999. Successful treatment with bacteriophage in purulent cerebrospinal meningitis in a newborn. Neurol. Neurochir. Pol. 3: 693-698.
31. Sulakvelidze, A., Z. Alavidze, and J. G. Morris Jr. 2001. Bacteriophage therapy. Antimicrob. Agents Chemother. 45: 649-659.
32. Theil, K. 2004. Old dogma, new tricks - 21st century phage therapy. Nat. Biotechnol. 22: 31-36.
33. Wang, J., B. Hu, M. Xu, Q. Yan, S. Liu, X. Zhu, ei al. 2006. Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa. Int. J. Mol. Med. 17: 309-317.
34. Weber-Dabrowska, B., M. Zimecki, and M. Mulczyk. 2000. Effective phage therapy is associated with normalization of cytokine production by blood cell cultures. Arch. Immunol. Ther. Exp. 48: 31-37.
35. Wills, Q. F., C. Kerrigan, and J. A. Soothill. 2005. Experimental bacteriophage protection against Staphylococcus aureus abscesses in a rabbit model. Antimicrob. Agents Chemother. 49: 1220-1221.